skip to Main Content
480.314.3070

Imaging Endpoints Assists FORMA Therapeutics As Olutasidenib Demonstrates Positive Phase 1b/2 Results, Including Blood-Brain Barrier Penetration And Stable Disease In Patients With IDH1-Mutated Glioma.

Imaging Endpoints Assists FORMA Therapeutics as Olutasidenib Demonstrates Positive Phase 1b/2 Results, Including Blood-Brain Barrier Penetration And Stable Disease In Patients With IDH1-Mutated Glioma. The Data Was Recently Presented at the 2019 Society for NeuroOncology Annual Meeting. WATERTOWN, Mass. –…   Read More

Back To Top